"Regeneron Pharmaceuticals Inc. said its monoclonal antibody drug continued to provide strong protection against Covid-19 infection for eight months, reducing the risk of contracting the disease by 81.6% compared with a placebo in a long-term study.
Regeneron said Monday that the data show the drug, called REGEN-COV, can provide long-lasting temporary immunity against Covid-19, which could make it an attractive option for people who don't respond to vaccines because they have impaired immune systems.
In September, Regeneron published data from the same study showing that the drug reduced the risk of Covid-19 infection by 81.4% for one month after patients received the drug, achieving the study's primary goal. The new study data confirmed that the same level of protection is durable for at least an additional seven months, Regeneron said. Over eight months, none of the subjects getting REGEN-COV were hospitalized for Covid, compared with six subjects receiving placebos, Regeneron said." [1]
1. U.S. News: Treatment Cut Covid Risk, Says Regeneron
Walker, Joseph. Wall Street Journal, Eastern edition; New York, N.Y. [New York, N.Y]. 09 Nov 2021: A.3.
Komentarų nėra:
Rašyti komentarą